Redemsiwir, deksametazon u pacjentów hospitalizowanych. A jakie terapie EBM w lżejszych/wcześniejszych postaciach Covid-19?

Peter S.Kim i wsp. Therapy for Early COVID-19. A Critical Need. JAMA 2020 online

Several antivirals approved or in development for other viral infections, such as HIV, hepatitis C virus, and ebolaviruses, are under investigation for early treatment of COVID-19 …

Immune-modulating drugs are being extensively examined for treatment of moderate to severe COVID-19 …

SARS-CoV-2–specific approaches, such as antiviral antibodies, are also being developed. Convalescent plasma, hyperimmune γ-globulin, and polyclonal antibody products are being tested …

Several clinical trials, including the National Institutes of Health–sponsored ACTIV-4 trial (COVID-19 Positive Outpatient Thrombosis Prevention Trial are testing factor Xa inhibitors and other anticoagulant strategies to prevent thromboembolic complications …

JAMA, 11 listopada 2020

Dodaj komentarz